A phase I/II trial of temsirolimus plus neratinib for patients with metastatic HER2-amplified or triple-negative breast cancer
PUMA NER 10-005
Clinical Trial Program
A phase I/II trial of temsirolimus plus neratinib for patients with metastatic HER2-amplified or triple-negative breast cancer
Phase I, Phase II
Status
Finished
Tumour subtype:
HER2+
Scenario
Localmente avanzado o metastático
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Sarat Chandarlapaty, MD, PhD (Memorial Sloan Kettering Cancer Center (MSKCC))
Sites
